ACKNOWLEDGMENTS
Gastric cancer, cancers, cancer death, Peritoneal carcinomatosis, tumors, gastric cancer
GASTRIC CANCER, CANCERS, PERITONEAL CARCINOMATOSIS, METASTASIS, DISEASE, STAGE IV GASTRIC CANCER, PERITONEAL CARCINOMATOSIS, TUMORS, GASTRIC CANCER
This study was supported by the State of Sao Paulo Research Foundation (FAPESP) – Grant Number: 2020/13249-0 (Principal Investigator: Andre Roncon Dias).Financial Source: This study is supported by the State of Sao Paulo Research Foundation (FAPESP) – Grant number: 2020/13249-0 (Principal Investigator: Andre Roncon Dias).Editorial Support: National Council for Scientific and Technological Development (CNPq).
Gastric cancer is one of the most common cancers, and despite advances in diagnosis and treatment, it remains an important cause of cancer death worldwide. Unfortunately, patients with gastric cancer are often diagnosed with clinical stage IV tumors. Peritoneal carcinomatosis is a definitive determinant of prognosis, and the current standard treatment in these cases is systemic chemotherapy. As systemic chemotherapy is not sufficient to contain the disease, a multimodal approach associating normothermic intraperitoneal chemotherapy with surgery may represent an alternative for these cases.
Intraperitoneal chemotherapy may increase the survival of patients with peritoneal carcinomatosis, in addition to offering the possibility of conversion surgery for some patients aiming at a curable intention after tumors are initially deemed oncologically unresectable, as long as the intraperitoneal chemotherapy shows robust efficacy. So far, the management of peritoneal metastasis has been challenging, and if intraperitoneal chemotherapy proves to be effective for some patients, this treatment approach could result in a drastic shift to stage IV gastric cancer.